Kabushiki Kaisha Toshiba

Immuno Japan Inc.

Shunji Mishiro

Tetsuo Nakamura

Koji Hashimoto

Minako Hijikata

Yasuhiko Oota

Michie Hashimoto

Noriko Matsuyama

Masanobu Sugimoto

A carrier for gene detection as a means for prediction before treatment whether interferon therapy is valid or not for a patient, a method for detection of interferon therapy for an individual, an apparatus for gene detection, and a kit for detection of validity of interferon therapy.

Carrier for gene detection and its use for detecting validity of interferon therapy

The present invention provides a polymorphic marker found in a region of the interferon receptor gene that can be used to assess the efficacy of interferon therapy. Thus, the present invention also relates to methods of assessing the efficacy of interferon therapy in an individual and means for accomplishing such a method.

Polymorphic marker that can be used to assess the efficacy of interferon therapy

The present invention provides polynucleotides having base sequences of sequence Nos. 1 to 4, as polynucleotides having polymorphism sites capable of being useful indicators for prediction of validity of interferon therapy.

Genetic polymorphism of MxA protein and use thereof

Novel nucleic acids, proteins, peptides, antigens, and antibodies related to non-A, non-B hepatitis, and non-A, non-B hepatitis diagnostic reagents using those materials.

Non-A non-B hepatitis related nucleic acids proteins peptides antigens

Non-A, non-B hepatitis related nucleic acids, proteins, peptides,

Non-A, Non-B Hepatitis Virus Genome RNA is disclosed along with cDNA and Virus Antigen Protein.

Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein

Non-A, Non-B hepatitis virus genome RNA is disclosed along with cDNA and virus antigen protein.

Growing community of inventors

Tokyo, Japan

Shunji Mishiro